The Johns Hopkins University

Kevin J Yarema

Udayanath Aich

Christopher Campbell

Srinivasa-Gopalan Sampathkumar

Alfredo Quinones-Hinojosa

Sagar Ramesh Shah

Christopher Weier

Christopher T Saeui

Sean S Choi

Michael Adam Meledeo

Jennifer H Elisseeff

Mark B Jones

Ruben T Almaraz

Jeannine Coburn

Disclosed are UAP inhibitors to inhibit glucose flux in the hexosamine biosynthetic pathway and methods of treating a disease using the inhibitors.

Use of UAP inhibitors to inhibit flux through the hexosamine biosynthetic pathway

Methods of glycoprotein production employing monosaccharides capable of producing a global increase in flux through the sialic acid pathway are provided.

Use of high flux SCFA-derivatized monosaccharides in recombinant glycoprotein production

A new class of molecules, C&#x2014;OH tributanoylated hexosamines, including, for example, GalNAc, GlcNAc and ManNAc, are demonstrated to increase cartilage-like tissue accumulation by IL-1&#x3b2;-stimulated chondrocytes. Furthermore, all three molecules reduced NFKB1 and I&#x3ba;B&#x3b1; driven gene expression, consistent with NF&#x3ba;B inhibitory properties of these analogs. GalNAc-a exposure produced the greatest ECM accumulation by IL-1&#x3b2;-stimulated chondrocytes. However, GalNAc-a exposure produced an opposite effect on MSC exposure, where a decrease in ECM accumulation was observed. These findings are in support of the function of NF&#x3ba;B signaling during limb development and growth plate chondrogenesis. The present invention shows the capability of this new class of hexosamine analogs as disease-modifying agents for treating cartilage damage.

Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications

Described herein are fatty acid carbohydrate hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof

Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders

Growing community of inventors

Woodstock, MD, United States of America

Kevin J Yarema